ARYx Therapeutics Inc (NASDAQ:ARYX), a biopharmaceutical company,
announced today that a conference call to discuss first quarter 2009
results will be held on Thursday, May 14, 2009 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 877-741-4241
Dial In (International): 719-325-4760
Passcode (if requested): 1974909
Preregistration is not required. This call is also being webcast and can
be accessed at ARYx Therapeutics’ web site at www.aryx.com.
Replays of the call will be available through June 30, 2009 at the ARYx
web site.
About ARYx Therapeutics, Inc.
ARYx Therapeutics is a biopharmaceutical company focused on developing a
portfolio of internally discovered products designed to eliminate known
safety issues associated with well-established, commercially successful
drugs. ARYx uses its RetroMetabolic Drug Design technology to design
structurally unique molecules that retain the efficacy of these original
drugs but are metabolized through a potentially safer pathway to avoid
specific adverse side effects associated with these compounds. ARYx
currently has four products in clinical trials: an oral anticoagulant
agent for patients at risk for the formation of dangerous blood clots,
tecarfarin (previously named ATI-5923); an oral anti-arrhythmic agent
for the treatment of atrial fibrillation, budiodarone (previously named
ATI-2042); a prokinetic agent for the treatment of various
gastrointestinal disorders, ATI-7505; and, an agent for the treatment of
schizophrenia and other psychiatric disorders, ATI-9242. Please visit
our web site at www.aryx.com
for additional information.
ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211
